JP2023078467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023078467A5 JP2023078467A5 JP2023057334A JP2023057334A JP2023078467A5 JP 2023078467 A5 JP2023078467 A5 JP 2023078467A5 JP 2023057334 A JP2023057334 A JP 2023057334A JP 2023057334 A JP2023057334 A JP 2023057334A JP 2023078467 A5 JP2023078467 A5 JP 2023078467A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- polypeptide
- seq
- polypeptides
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024195763A JP2025020347A (ja) | 2017-01-26 | 2024-11-08 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450804P | 2017-01-26 | 2017-01-26 | |
| US62/450,804 | 2017-01-26 | ||
| US201762487135P | 2017-04-19 | 2017-04-19 | |
| US62/487,135 | 2017-04-19 | ||
| PCT/US2018/015595 WO2018140821A1 (en) | 2017-01-26 | 2018-01-26 | Tissue-specific wnt signal enhancing molecules and uses thereof |
| JP2019541341A JP7305543B2 (ja) | 2017-01-26 | 2018-01-26 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541341A Division JP7305543B2 (ja) | 2017-01-26 | 2018-01-26 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195763A Division JP2025020347A (ja) | 2017-01-26 | 2024-11-08 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023078467A JP2023078467A (ja) | 2023-06-06 |
| JP2023078467A5 true JP2023078467A5 (https=) | 2023-08-25 |
| JP7635291B2 JP7635291B2 (ja) | 2025-02-25 |
Family
ID=62978866
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541341A Active JP7305543B2 (ja) | 2017-01-26 | 2018-01-26 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| JP2023057334A Active JP7635291B2 (ja) | 2017-01-26 | 2023-03-31 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| JP2024195763A Withdrawn JP2025020347A (ja) | 2017-01-26 | 2024-11-08 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541341A Active JP7305543B2 (ja) | 2017-01-26 | 2018-01-26 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024195763A Withdrawn JP2025020347A (ja) | 2017-01-26 | 2024-11-08 | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11958891B2 (https=) |
| EP (1) | EP3574019A4 (https=) |
| JP (3) | JP7305543B2 (https=) |
| CN (1) | CN110234662A (https=) |
| AU (1) | AU2018211985B2 (https=) |
| CA (1) | CA3050133A1 (https=) |
| WO (1) | WO2018140821A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7617603B2 (ja) | 2017-01-11 | 2025-01-20 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｒ－スポンジン（ｒｓｐｏ）サロゲート分子 |
| JP7305543B2 (ja) | 2017-01-26 | 2023-07-10 | スロゼン オペレーティング， インコーポレイテッド | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| EP3732201A4 (en) | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | WNT SURROGATES AND THEIR USES |
| CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| CN111655729B (zh) | 2017-12-19 | 2023-10-20 | 瑟罗泽恩奥普瑞汀公司 | 抗卷曲蛋白抗体和使用方法 |
| JP2021530223A (ja) * | 2018-07-09 | 2021-11-11 | スロゼン， インコーポレイテッド | 組織特異性Ｗｎｔシグナル増強分子及びその使用 |
| US20220041753A1 (en) * | 2018-12-27 | 2022-02-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bispecific antibody for membrane clearance of target receptors |
| JP7663501B2 (ja) * | 2019-02-11 | 2025-04-16 | スロゼン オペレーティング， インコーポレイテッド | 眼障害におけるｗｎｔシグナル伝達の調節 |
| US20220175884A1 (en) * | 2019-04-02 | 2022-06-09 | Surrozen Operating, Inc. | Modulation of wnt signaling in auditory disorders |
| CN120025448A (zh) * | 2019-06-11 | 2025-05-23 | 安托拉诊疗公司 | 多价fzd和wnt结合分子及其用途 |
| US11713461B2 (en) | 2019-06-21 | 2023-08-01 | Regeneran Pharmaceuticals, Inc. | Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors |
| KR102192471B1 (ko) * | 2019-10-18 | 2020-12-17 | 주식회사 인코스팜 | 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물 |
| US20240000890A1 (en) * | 2020-01-09 | 2024-01-04 | Retinal Solutions, LLC | Neural regeneration with synthetic protein administration |
| CN115427446A (zh) * | 2020-02-24 | 2022-12-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt超级激动剂 |
| CN116745318A (zh) * | 2020-11-10 | 2023-09-12 | 斯克里普斯研究学院 | 用于阿片样物质治疗的抗体 |
| TW202233656A (zh) * | 2020-11-16 | 2022-09-01 | 美商蘇羅森營運公司 | 肝特異性wnt訊號增強分子及其用途 |
| CN112386687B (zh) * | 2020-12-09 | 2021-05-04 | 爱龄医美国际健康咨询服务(北京)有限公司 | 一种干细胞外泌体及其在药品和化妆品中的应用 |
| CN113307882B (zh) * | 2021-05-12 | 2022-12-20 | 东北大学 | 靶向治疗Rspo过度激活导致的结直肠癌的融合蛋白SZ1及其偶联纳米药物 |
| CN113293214A (zh) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | 一种检测神经母细胞瘤复发转移基因wnt2扩增的引物探针及其应用 |
| AU2022311529A1 (en) * | 2021-07-15 | 2024-01-25 | Centre National De La Recherche Scientifique (Cnrs) | Recombinant variants of r-spondin proteins and their use |
| JPWO2023080159A1 (https=) * | 2021-11-02 | 2023-05-11 | ||
| CN116789843B (zh) * | 2022-03-16 | 2024-09-17 | 伯桢生物科技(杭州)有限公司 | Wnt重组蛋白及其应用 |
| CN116836274B (zh) * | 2022-03-23 | 2024-11-22 | 东莞市朋志生物科技有限公司 | 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒 |
| CN119403570A (zh) * | 2022-06-21 | 2025-02-07 | 瑟罗泽恩奥普瑞汀公司 | Wnt信号传导在角膜病中的调节作用 |
| CN119744268A (zh) * | 2022-09-09 | 2025-04-01 | 德国癌症研究中心公共法律基金会 | 靶向pd-l1降解 |
| WO2025146152A1 (zh) * | 2024-01-04 | 2025-07-10 | 上海宝济药业股份有限公司 | 一种药物组合物及其应用 |
| CN120647751B (zh) * | 2025-08-18 | 2025-12-02 | 成都迈科康生物科技有限公司 | 抗人乳头瘤病毒e1蛋白的抗体或其试剂盒和相关应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044409A1 (en) | 2001-05-01 | 2003-03-06 | Carson Dennis A. | Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens |
| PL2157192T3 (pl) | 2003-10-10 | 2014-01-31 | Deutsches Krebsforsch | Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin) |
| DE102004050620A1 (de) | 2004-10-13 | 2006-04-20 | Eberhard-Karls-Universität Tübingen | Monoklonaler Antikörper gegen Frizzled-Rezeptoren |
| DE102005035568A1 (de) | 2005-07-25 | 2007-02-01 | M-Phasys Gmbh | Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns |
| EP3611266B1 (en) | 2005-08-23 | 2022-11-09 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| CN101573383B (zh) | 2006-06-21 | 2015-05-13 | 肿瘤疗法科学股份有限公司 | 靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途 |
| AU2007285217B2 (en) | 2006-08-14 | 2013-02-07 | Forerunner Pharma Research Co., Ltd | Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies |
| WO2008093646A1 (ja) | 2007-02-01 | 2008-08-07 | National University Corporation NARA Institute of Science and Technology | Wntシグナル伝達系活性化ペプチド |
| CN103002911B (zh) | 2008-09-26 | 2015-08-26 | 昂考梅德药品有限公司 | 卷曲蛋白结合药剂及其应用 |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| ES2579909T3 (es) | 2009-02-03 | 2016-08-17 | Koninklijke Nederlandse Akademie Van Wetenschappen | Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre |
| WO2010092457A1 (en) | 2009-02-10 | 2010-08-19 | Nokia Corporation | Method, apparatus and computer program product for transfer of capability support information in a multi-rat environment |
| EP2305274A1 (en) | 2009-09-21 | 2011-04-06 | Centre National de la Recherche Scientifique (CNRS) | Use of WNT stimulators for treating demyelinating diseases |
| PT2510012T (pt) | 2009-12-09 | 2017-07-13 | Bayer Pharma AG | Anticorpos anti-c4.4a e utilizações dos mesmos |
| CA2794674A1 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| CA2796464C (en) | 2010-04-16 | 2021-08-03 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| SG10201602394QA (en) | 2011-03-29 | 2016-05-30 | Roche Glycart Ag | Antibody FC Variants |
| EP2694660B1 (en) | 2011-04-03 | 2018-08-08 | The General Hospital Corporation | Efficient protein expression in vivo using modified rna (mod-rna) |
| GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CN109111523B (zh) | 2011-10-14 | 2022-06-07 | 诺华股份有限公司 | 用于Wnt途径相关疾病的抗体和方法 |
| WO2013071047A1 (en) | 2011-11-11 | 2013-05-16 | Children's Medical Center Corporation | Compositions and methods for in vitro transcription of rna |
| WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
| EP2820151B1 (en) | 2012-02-28 | 2020-03-25 | Novartis AG | Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status |
| CA2868391A1 (en) | 2012-04-02 | 2013-10-10 | Stephane Bancel | Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same |
| EP2882775B1 (en) | 2012-08-09 | 2018-02-14 | Roche Glycart AG | Asgpr antibodies and uses thereof |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| MA39896A (fr) | 2014-04-21 | 2017-03-01 | Abbvie Stemcentrx Llc | Nouveaux anticorps antii-rnf43 et méthodes d'utilisation |
| US11142577B2 (en) | 2014-09-12 | 2021-10-12 | The Board Of Trustees Of The Leland Stanford Junior University | WNT signaling agonist molecules |
| US10259874B2 (en) | 2014-10-27 | 2019-04-16 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| EP3221361B1 (en) | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| CA2983008A1 (en) | 2015-04-17 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Combination treatments with seribantumab |
| CA3002957A1 (en) * | 2015-10-23 | 2017-04-27 | Koninklijke Nederlandse Akademie Van Wetenschappen | Binding molecules that inhibit cancer growth |
| AU2016365834B2 (en) | 2015-12-08 | 2023-09-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| US20170349659A1 (en) | 2016-06-03 | 2017-12-07 | The Board Of Trustees Of The Leland Stanford Junior University | Wnt signaling agonist molecules |
| WO2018107116A1 (en) | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| JP7617603B2 (ja) | 2017-01-11 | 2025-01-20 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｒ－スポンジン（ｒｓｐｏ）サロゲート分子 |
| JP7305543B2 (ja) | 2017-01-26 | 2023-07-10 | スロゼン オペレーティング， インコーポレイテッド | 組織特異的Ｗｎｔシグナル増強分子およびその使用 |
| EP3619238A4 (en) | 2017-05-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | CYTOTOXICITY INDUCING THERAPEUTIC |
| GB201708330D0 (en) | 2017-05-24 | 2017-07-05 | Koninklijke Nederlandse Akademie Van Wetenschappen | Fusion protein for enhancing intestinal regeneration |
| EP3732201A4 (en) | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | WNT SURROGATES AND THEIR USES |
| CN111655729B (zh) | 2017-12-19 | 2023-10-20 | 瑟罗泽恩奥普瑞汀公司 | 抗卷曲蛋白抗体和使用方法 |
| CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| CA3104526A1 (en) | 2018-07-05 | 2020-01-09 | Surrozen, Inc. | Multi-specific wnt surrogate molecules and uses thereof |
| JP2021530223A (ja) | 2018-07-09 | 2021-11-11 | スロゼン， インコーポレイテッド | 組織特異性Ｗｎｔシグナル増強分子及びその使用 |
| US20220064337A1 (en) | 2018-12-19 | 2022-03-03 | Surrozen, Inc. | Antigen binding formats for receptor complexes |
| JP7663501B2 (ja) | 2019-02-11 | 2025-04-16 | スロゼン オペレーティング， インコーポレイテッド | 眼障害におけるｗｎｔシグナル伝達の調節 |
| US20220195053A1 (en) | 2019-03-11 | 2022-06-23 | Surrozen Operating Inc. | Modulation of wnt signaling in gastrointestinal disorders |
| US20220175884A1 (en) | 2019-04-02 | 2022-06-09 | Surrozen Operating, Inc. | Modulation of wnt signaling in auditory disorders |
| CN120025448A (zh) | 2019-06-11 | 2025-05-23 | 安托拉诊疗公司 | 多价fzd和wnt结合分子及其用途 |
| US11050604B2 (en) | 2019-07-01 | 2021-06-29 | Rampart Communications, Inc. | Systems, methods and apparatuses for modulation-agnostic unitary braid division multiplexing signal transformation |
| CN115427446A (zh) | 2020-02-24 | 2022-12-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt超级激动剂 |
| TW202233656A (zh) | 2020-11-16 | 2022-09-01 | 美商蘇羅森營運公司 | 肝特異性wnt訊號增強分子及其用途 |
| JP2024509266A (ja) | 2021-03-10 | 2024-02-29 | スロゼン オペレーティング， インコーポレイテッド | 胃腸障害におけるｗｎｔシグナル伝達のモジュレーション |
-
2018
- 2018-01-26 JP JP2019541341A patent/JP7305543B2/ja active Active
- 2018-01-26 WO PCT/US2018/015595 patent/WO2018140821A1/en not_active Ceased
- 2018-01-26 EP EP18744610.9A patent/EP3574019A4/en active Pending
- 2018-01-26 US US16/481,001 patent/US11958891B2/en active Active
- 2018-01-26 AU AU2018211985A patent/AU2018211985B2/en active Active
- 2018-01-26 CA CA3050133A patent/CA3050133A1/en active Pending
- 2018-01-26 CN CN201880008831.XA patent/CN110234662A/zh active Pending
-
2023
- 2023-03-31 JP JP2023057334A patent/JP7635291B2/ja active Active
-
2024
- 2024-03-06 US US18/597,679 patent/US20240279303A1/en active Pending
- 2024-11-08 JP JP2024195763A patent/JP2025020347A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023078467A5 (https=) | ||
| JP2021530223A5 (https=) | ||
| JP2020506701A5 (https=) | ||
| JPWO2020014271A5 (https=) | ||
| Mertens et al. | Plakophilins 2a and 2b: constitutive proteins of dual location in the karyoplasm and the desmosomal plaque. | |
| AU2016289492B2 (en) | Vaccine against RSV | |
| JP2025184979A5 (https=) | ||
| RU2010122053A (ru) | Иммуносупрессорные полипептиды и нуклеиновые кислоты | |
| JP2020023517A5 (https=) | ||
| JP2016052315A5 (https=) | ||
| NO995689D0 (no) | Forbindelser for immunoterapi og diagnose av tuberkulose og metoder for deres anvendelse | |
| JP2014510518A5 (https=) | ||
| JP2005120106A5 (https=) | ||
| KR960704038A (ko) | 세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek) | |
| RU2012113162A (ru) | Белок слияния, содержащий тимусный стромальный лимфопоэтический белок, вакцина, содержащая эскпрессионный вектор для экспресии белка, и вакцина, содержащая указанный вектор для экспрессии | |
| JP2017512063A5 (https=) | ||
| JP2018537087A5 (https=) | ||
| JP2023029902A5 (https=) | ||
| JP2005245460A5 (https=) | ||
| JP2009525757A5 (https=) | ||
| CN115443288A (zh) | 一种免疫球蛋白降解酶IdeE的突变体 | |
| RU2218402C2 (ru) | Выделенный полипептид, имеющий гомологию относительно комплемент родственного белка адипоцитов (варианты), гибридный белок (варианты), экспрессирующий вектор, способ получения полипептида, поликлональное антитело, фрагмент выделенного полинуклеотида (варианты) | |
| FI4034555T3 (fi) | Dap10/dap12-fuusiopolypeptidit | |
| RU2008138536A (ru) | Химерные вакцинные антигены против вируса классической чумы свиней | |
| JP2020517260A5 (https=) |